BioNTech Charts Its Future in Cancer as Founders Step Back and FDA Nods to New Vaccine

BioNTech faces a pivotal week as FDA clears next COVID shot, ASCO presents three oncology readouts, and founders prepare to exit. Can it build a lasting post-pandemic business?

This is the week BioNTech stops being a two-trick pony on paper and starts proving it in practice. The FDA just ruled on its next COVID shot, the ASCO conference is delivering three oncology readouts, and the founders are preparing to walk out the door by year-end. All three storylines converge into a single question: can the company build a lasting business beyond the pandemic?

A clear path for the autumn vaccine campaign

On May 28, the FDA’s VRBPAC advisory committee voted to update the COVID-19 vaccine formula to target the XFG variant for the 2026/2027 season, following a similar WHO recommendation. BioNTech and its partner Pfizer signaled they are ready to manufacture. That matters for the top line: the infectious disease segment brought in roughly €118 million in the first quarter, and the regulatory clarity gives management a reliable revenue baseline for the rest of the year.

ASCO takes center stage

That same week, the American Society of Clinical Oncology meeting in Chicago became the real test of BioNTech’s strategic pivot. The company is presenting three data packages that investors will scrutinise closely:

• Gotistobart (BNT316): Phase-2 results from the PRESERVE-004 study show sustained tumour activity and survival data in platinum-resistant ovarian cancer.
• BNT324/DB-1311: An antibody-drug conjugate (ADC) targeting prostate cancer.
• BNT323 (Trastuzumab pamirtecan): Data in recurrent endometrial carcinoma.

BioNTech aims to have 15 ongoing phase-3 studies by the end of 2026, up from the current 13. The cash pile of nearly €16.8 billion provides the firepower to reach that goal.

Financial scorecard and stock technicals

Behind the clinical optimism lies a sobering profit-and-loss statement. The first quarter ended with a net loss of about €532 million, although management reaffirmed the full-year outlook and continued to execute a multi-billion-euro share buyback programme. The stock was changing hands around €80.70, roughly 21% below its 52-week high of €101.90.

Technically, the shares are sitting right on their 50-day moving average near €81, still well below the 200-day average of about €86. The March low of €72.50 has held for now, but a sustained uptrend has yet to materialise. The ASCO data will be the next catalyst that either breaks the resistance or confirms the drift.

A leadership handoff

Adding a layer of narrative to the week’s events, founders U?ur ?ahin and Özlem Türeci confirmed they will transfer to a separate mRNA research venture before the end of the year. BioNTech retains a minority stake and secures rights to certain next-generation technologies from the new entity. The move signals an orderly transition of the scientific helm, but it also introduces an element of uncertainty around long-term strategic continuity.

In the months ahead, seven more late-stage data readouts are scheduled for the second half of 2026. The ASCO presentations are the first high-profile opportunity for BioNTech to demonstrate that its oncology pipeline can generate the same kind of conviction that its vaccine once did.